Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Inclusion Criteria: * Adults over 50 years old * Able to sign informed consent and comply with the study protocol for the duration of the two years. * Nonexudative age-related macular degeneration (AMD) in one eye (study eye) •At time of enrollment, fellow non-study eye must have recently diagnosed (not more than 2 years prior to enrollment), angiographically documented, previously untreated prior to diagnosis, CNV lesion (i.e., leakage on fluorescein angiography AND subretinal, intraretinal, or sub-RPE fluid on OCT) secondary to age-related macular degeneration. Exclusion Criteria: * Previous treatment with verteporfin PDT, Macugen®, Lucentis®, intravitreal Avastin®, intravitreal Eylea®, thermal laser, external beam radiation or other AMD therapy in the study eye. * History of macular hole in study eye. * History of vitrectomy in study eye. * Lens extraction or implantation within the last 3 months. * Capsulotomy within the last 1 month. * Lens or other media opacity that would preclude good fundus photography or angiography within the next 2 years. * Nevus \> 2 disc areas within 3000 microns of the foveal center or with fluid or leakage on fluorescein angiography. * Macular edema or signs of diabetic retinopathy more severe than 10 red dots (microaneurysms or blot hemorrhages). * Retinal changes related to high myopia and no myopic correction greater than 8.00 diopters spherical equivalent \[sphere + ½ cylinder\]. * Any progressive ocular disease that would affect visual acuity within the next 2 years. * Previous participation in any studies of investigational drugs likely to have ocular effects within 30 days preceding the initial study treatment. * Concurrent use of systemic anti-VEGF agents. * Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye. * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye. * For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye cannot exceed 8 diopters of myopia. * Uncontrolled glaucoma in the study eye (defined as intraocular pressure \> 25 mmHg) despite treatment with antiglaucoma medication). * Patients who are unable to be photographed to document CNV due to known allergy to fluorescein dye, lack of venous access or cataract obscuring the CNV. * Patients with other ocular diseases that can compromise the visual acuity of the study eye such as amblyopia and anterior ischemic optic neuropathy. * Current treatment for active systemic infection. * Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders. * History of recurrent significant infections or bacterial infections. * Inability to comply with study or follow-up procedures. * Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial